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Available online 19 March 2016Background: Trials of remote ischemic pre-conditioning (RIPC) have suggested this intervention reduces compli-
cations of angioplasty and coronary artery by-pass grafting (CABG). The aim of this work was to conduct a sys-
tematic review and meta-analysis of the effects of RIPC on mortality and myocardial damage in patients
undertaking coronary artery bypass grafting with/without valve surgery.
Methods: A systematic review and subsequentmeta-analysis of randomized controlled trials of RIPC versus usual
care or sham RIPC was performed.
Results: Eighteen studies, totalling 4551 participants were analysed. RIPC reduced post troponin release as indi-
cated by area under the curve at 72 h (μg·L−1) Mean Difference (MD) −3.72 (95% CI −3.92 to −3.53,
p b 0.00001). However there was no signiﬁcant difference between RIPC and control when mortality odds
ratio (OR) 1.27 (95% CI 0.87 to 1.86, p = 0.22); the incidence of new onset atrial ﬁbrillation OR 0.82 (95%
CI 0.67 to 1.01, p = 0.06); inotropic support OR 1.27 (95% CI 0.84 to 1.91, p = 0.25); intensive care unit stay
in days MD −0.02 (95% CI −0.12 to 0.07, p = 0.61); Hospital stay in days MD 0.18 (95% CI −0.30 to 0.66,
p = 0.47) and serum creatinine MD−0.00 (95% CI−0.07 to 0.07, p = 0.97) were compared.
Conclusions: RIPC reduces does not confer any clinical beneﬁt in patients undertaking CABG with/without valve
surgery.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Troponins1. Introduction
Remote ischaemic pre-conditioning (RIPC) is a novel prophylactic
treatment during which brief periods of ischaemia in a remote vascular
bed provides protection against a subsequent longer bout of ischaemia
in the heart. Initially demonstrated in a separate cardiovascular bed
[1], it was later shown that protection could also be achieved by precon-
ditioning in a remote organ [2] or in a remote limb [3]. Transfer of the
signalling stimulus to the heart is thought to involve the somatosensory
system, the spinal cord, the autonomous nervous system and humoral
elements. Candidates for the humoral signal include nitric oxide,
MicroRNA-144, and stromal derived factor-1α [4]. A further complex
signal transduction occurs in the heart possibly involving the reperfu-
sion injury salvage kinase (RISK) pathway [4]. Since the early animal
studies [1–3], RIPC has been shown to reduce myocardial injury in pa-
tients undergoing both elective [5] and primary percutaneous interven-.
liability and freedom from bias
. This is an open access article undertions [6] as well as coronary artery bypass grafting (CABG) [7]. In
addition to these cardioprotective effects, RIPC has also been used in
the management of blood pressure [8], improvement of endothelial
function and blood ﬂow [9], and neuroprotection [10].
There have been a number of meta-analyses that have investigated
the effects of remote ischaemic preconditioning during open heart sur-
gery. An early study conducted in 2008 only managed to pool data from
four studies [11]. Later studies conducted in 2012 predominately focussed
on myocardial injury as indicated by troponin release [12–15] and there
are manymore clinical outcomes that were not assessed. To some extent
thiswas addressed in a recentmeta-analysis byDeng et al. [16]who com-
pared aortic cross-clamping versus remote ischaemic preconditioning,
however they did not investigate important clinical outcomes such as
inotrope use and post-discharge mortality. Since then another six ran-
domized trials have been published including 2 recent large scale multi-
centre trials [17–22], which also suggest another look is justiﬁed.
The aims of this work were to; (i) examine the effects of RIPC on
a range of clinical outcomes and markers of myocardial and renal
damage in patients undertaking coronary artery bypass grafting with/
without valve surgery; (ii) relate these ﬁndings to established thresholds
of clinical signiﬁcance andprovide an evidencebased context for RIPCuse.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Characteristics of included studies.
Study RIPC protocol Comparator N RIPC
(control)
Population Age RIPC
(control)
Male %
RIPC
(control)
All outcome
measures
Ahmad et al., 2014
[17]
Upper limb
3 × 5 min &
5 min reperfusion
Sham (Cuff
deﬂated)
35 (32) Triple vessel CABG 54.46 ± 8.83 (55.16 ± 10.95) 77 (78) CK-MB
Creatinine
IABP
Inotropic support
Mortality
Pakistan
Ali et al., 2010 [23] Upper limb
3 × 5 min &
5 min reperfusion
Sham (Cuff
deﬂated)
50 (50) Double/triple vessel CABG 56.02 ± 8.24 (51.6 ± 9.58) 94 (84) CK-MB
IABP
Inotropic support
Pakistan
Candilio et al., 2015
[7]
Upper and lower limb
3 × 5 min &
5 min reperfusion
Sham (Cuff
deﬂated)
89 (89) Single-quadruple vessel CABG
and/or valve surgery
65 ± 10 (66 ± 10) 81 (75) AF
Creatinine
hsTnT
ICU stay
Inotropic support
MACE
Mortality
UK
Gedik et al., 2014
[18]
Upper limb
3 × 5 min &
5 min reperfusion
Sham (Cuff
deﬂated)
10 (10) Double/triple vessel CABG 62.6 ± 3.4 (65.5 ± 4.2) 90 (80) Autophagy
markers
cTnI
Signalling markers
Germany
Hausenloy et al.,
2007 [24]
Upper limb
3 × 5 min &
5 min reperfusion
Sham (Cuff
deﬂated)
27 (30) Single-quadruple vessel CABG 67 ± 11.8 (67 ± 9.4) 78 (80) cTnT
UK
Hausenloy et al.,
2015 [21]
Upper limb
4 × 5 min & 5 min
reperfusion
Sham (Cuff
deﬂated)
801 (811) CABG and valve surgery 76.1 ± 6.1 (76.3 ± 7) 70.4 (72.7) Acute kidney injury
cTnT
Hospital stay
ICU stay
Inotropic support
MACE
UK
Holmberg et al.,
2014 [19]
Upper limb
3 × 5 min &
5 min reperfusion
No RIPC 20 (21) CABG and valve surgery 68 ± 11 (72 ± 9) 75 (67) AF
cTnT
CK-MB
Hospital stay
ICU stay
Inotropic support
Denmark
Karuppasamy et al.,
2011 [25]
Upper limb
3 × 5 min &
5 min reperfusion
Sham (Cuff
deﬂated)
27 (27) Double-quintuple vessel CABG 66.9 ± 11.2 (67.3 ± 10.3) 81 (85) BNP
cTnI
CK-MB
Cytokines
Growth factors
Hospital stay
Inotropic support
ICU stay
UK
Kottenberg et al.,
2012 [26]
Upper limb
3 × 5 min &
5 min reperfusion
No RIPC 20 (19) Triple vessel CABG 64 ± 9 (65 ± 9) 95 (84) cTnI
Creatinine
Isoﬂurane
anaesthetic
Propofol anaesthetic Upper limb
3 × 5 min &
5 min reperfusion
No RIPC 14 (19) Triple vessel CABG 65 ± 15 (64 ± 12) 64 (84) cTnI
CreatinineGermany
Lomivorotov et al.,
2012 [27]
Upper limb
3 × 5 min &
5 min reperfusion
Sham (Cuff
deﬂated)
40 (40) Mean 2.7 vessel CABG 56.5 ± 8.7 (58.1 ± 6.4) 90 (93) cTnI
CK-MB
ICU stay
Inotropic support
Mortality
Russia
Lucchinetti et al.,
2012 [28]
Lower limb
4 × 5 min & 5 min
reperfusion
Sham (Cuff
deﬂated)
27 (28) Mean 3.6 vessel CABG 59 ± 7 (62 ± 10) 96 (86) AF
Creatinine
hsCRP
hscTnT
Mortality
NT-proBNP
S100
Canada
Meybohm et al.,
2013 [29]
Upper limb
4 × 5 min &
5 min reperfusion
Sham (Cuff
inﬂated
to 20 mm Hg)
90 (90) CABG and valve surgery 70 (68) 77 (86) AF
cTnT
Hospital stay
Neurocognitive
changes
Germany
Meybohm et al.,
2015 [22]
Upper limb
4 × 5 min &
5 min reperfusion
Sham (Dummy
arm)
692 (693) CABG and valve surgery 65.8 ± 10.7 (66 ± 10) 73.4 (75) AF
AKF
Mortality
MI
Stroke
Germany
Rahman et al., 2010
[30]
Upper limb
3 × 5 min &
No RIPC 80 (82) Triple to quadruple vessel
CABG
63 (65) 89 (88) AF
cTnT
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Table 1 (continued)
Study RIPC protocol Comparator N RIPC
(control)
Population Age RIPC
(control)
Male %
RIPC
(control)
All outcome
measures
5 min reperfusion Creatinine
ECG
Echocardiography
Haemodynamics
IABP
Inotropic support
Mortality
UK
Slagsvold et al.,
2014 [20]
Upper limb
3 × 5 min &
5 min reperfusion
Sham (Cuff
deﬂated)
30 (30) Double to quadruple vessel
CABG
64.2 ± 9.0 (68.1 ± 8.2) 90 (77) AF
cTnT
CK-MB
miRs
Mitochondrial
respiration
NT-proBNP
Norway
Thielmann et al.,
2010 [31]
Upper limb
3 × 5 min &
5 min reperfusion
Sham (Cuff
deﬂated)
27 (26) Double to triple vessel CABG 63.4 ± 11.3 (64.1 ± 12.3) 85 (85) AF
cTnT
CK-MB
Creatinine
CRP
ECG
Hospital stay
ICU stay
MACE
Mortality
Germany
Thielmann et al.,
2013 [32]
Upper limb
3 × 5 min &
5 min reperfusion
Sham (Cuff
deﬂated)
162 (167) Triple vessel CABG 68.2 ± 10.3 (69.1 ± 9.2) 83 (80) cTnI
Creatinine
ECG
Hospital stay
ICU stay
MACE
Mortality
Germany
Venugopal et al.,
2009 [33]
Upper limb
3 × 5 min &
5 min reperfusion
Sham (Cuff
deﬂated)
23 (22) Single to quadruple vessel and
valve surgery
62 ± 9.7 (64 ± 9.0) 83 (86) cTnT
UK
Legend: AF, atrial ﬁbrillation; AKF, acute kidney failure; BNP, B-type natriuretic peptide; CABG, coronary artery bypass grafting; CK-MB, creatine kinase muscle brain band; cTnI, cardiac
troponin I; cTnT, cardiac troponin T; ECG, electrocardiography; hsCRP, high sensitivity C-reactive protein; hscTnT, high sensitivity troponin T; IABP, intra-aortic balloon pump; ICU, inten-
sive care unit; I/R, ischaemia reperfusion; MACE, major adverse coronary events; MI, myocardial infarction; miRs, microRNAs; NT-proBNP, N-terminal probrain natriuretic peptide.
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2.1. Search strategy
To identify potential studies systematic searches were carried
out using the following databases: EMBASE, PubMed, Web of Science
and the Cochrane Central Registry of Controlled Trials (CENTRAL).Fig. 1. Post discharThe search was supplemented by scanning the reference lists of
eligible studies. The search strategy included the key concepts of
“remote ischaemic preconditioning” and “coronary artery bypass
grafting”. All identiﬁed papers were assessed independently by
two reviewers. A third reviewer was consulted to resolve disputes.
Searches of published papers were conducted up until November 1st,
2015.ge mortality.
Fig. 2. Length of hospital stay (days).
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Only randomized controlled trials (RCTs) of RIPC in patients under-
going coronary artery bypass grafting with/without valve surgery were
included. There were no language restrictions. Animal studies, review
papers and non-randomized controlled trials were excluded. Studies
that do not have any of the desired outcome measures or participants
whowere treated byothermodalities such as percutaneous coronary in-
tervention were excluded. Authors were contacted to provide missing
data or to clarify if data was duplicated in multiple publications. Incom-
plete data, or data from an already included study, were excluded. Stud-
ies that included interventions other than RIPC were excluded.
2.3. Participants/population
This meta-analysis analysed RCTs of both male and female adult
(≥18 years) patientswith coronary artery diseasewhowere undergoing
coronary artery bypass grafting with/without valve surgery. Other
treatment modalities and interventions for coronary artery disease
such as RIPC in percutaneous coronary intervention were excluded.
2.4. Intervention(s), exposure(s)
This meta-analysis considered all RCTs where patients with stable
angina or acute coronary syndrome being treated with coronary artery
bypass grafting with/without valve surgery were exposed to RIPC.Fig. 3. Length of ICMore speciﬁcally, all RCTs where the intervention of expanding a
blood pressure cuff or applying a medical tourniquet in a remote limb
was carried out before coronary artery bypass grafting.
2.5. Comparator(s)/control
The meta-analysis utilised RCT's that compare RIPC during coronary
artery bypass graftingwith/without valve surgerywith a usual care con-
trol group receiving sham or no RIPC during coronary artery bypass
grafting with/without valve surgery.
2.6. Search results
Our initial search found 74 articles. Of these 7 studies were excluded
on the basis of title and abstract. Forty two studies were excluded as
they were not RCTs. Of these RCTs we excluded 7 studies: 2 studies in-
cluded post-conditioning; 2 studies concentrated on STAT5; 1 study
each concentrated on kinin receptor expression in neutrophils, on gly-
colysis, or on nitric oxide synthetase respectively (see supplementary
Table S1). Eighteen studies were included in our analysis [7,17–33].
2.7. Outcome(s)
The primary outcomes analysed were:
1. Mortality.
2. Hospital stay.U stay (days).
Fig. 4. Inotrope usage events post surgery.
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4. Inotrope usage.
5. New onset atrial ﬁbrillation.
6. Cardiac troponins (cTnT and cTnI. Area under the curve).
7. Serum creatinine.2.8. Risk of bias (quality) assessment
The JADAD scale was used to assess study quality and reporting [34].
2.9. Strategy for data synthesis
Odds ratios were calculated for dichotomous data. Mean differences
were calculated for continuous data. Meta-analyses were completed for
continuous data by calculating the mean difference between interven-
tion and control groups frompost-intervention data only. It is an accept-
ed practice to only use post-intervention data formeta-analysis, but this
method assumes that random allocation of participants always creates
intervention groups matched at baseline for age, disease severity. All
analyses were conducted using Revman 5.0 (Nordic Cochrane Centre
Denmark). A ﬁxed effects inverse variance model was used unlessFig. 5. Incidence of new onheterogeneity was N75%, then a random effects model was used. Het-
erogeneity was quantiﬁed using the Cochrane Q test [33]. We used a
5% level of signiﬁcance and 95% conﬁdence intervals; ﬁgures were pro-
duced using Revman 5.3.
3. Results
The eighteen studies included in the analyses had an aggregate of
4551 participants, 2267 of which received RIPC and 2283 were con-
trol/sham group participants. Table 1 summarizes the characteristics
of the included studies. Supplementary Table S1 lists the excluded
RCTs and reasons for exclusion. Fifteen studies used a sham control
group, as opposed to usual care. Only two studies utilized the lower
limb for RIPC. The RIPC protocols were very similar in terms of periods
of cuff occlusion and periods of reperfusion.
3.1. Long term postoperative outcomes
Eight studies reported post discharge mortality. The odds ratio (OR)
for the pooled analysis was 1.27 (95% conﬁdence interval [CI] 0.87 to
1.86, p = 0.22), see Fig. 1.set atrial ﬁbrillation.
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(days)
Six studies reported the length of hospital stay in days. The MD for
the pooled analysis was 0.18 (95% CI −0.30 to 0.66, p = 0.47) (see
Fig. 2). Seven studies reported the length of ICU stay in days. The MD
for the pooled analysis was −0.02 (95% CI −0.12 to 0.07, p = 0.61)
(see Fig. 3).
3.3. Immediate postoperative outcomes— inotrope usage and dysrhythmia
Six studies reported the use of inotropes to support patients, the OR
for the pooled analysis was 1.27 (95% CI 0.84 to 1.91, p = 0.25) (see
Fig. 4). Eight studies reported the incidence of new onset atrial ﬁbrilla-
tion. The OR for the pooled analysis was 0.82 (95% CI 0.67 to 1.01,
p = 0.06), see Fig. 5.
3.4. Biomarkers — troponin release and serum creatinine
Nine studies reported the area under the curve for troponin release
after surgery. The MD for the pooled analysis was −3.72 (95% CI
−3.92 to−3.53, p b 0.00001) (see Fig. 6). Five studies (six intervention
groups) reported the serum creatinine concentration, the MD for the
pooled analysis was 0.00 (95% CI−0.07 to 0.07, p = 0.97) (see Fig. 7).
4. Discussion
Ourmeta-analysis is the ﬁrst to include the results of two large scale
multi-centre trials investigating the role of RPIC in CABG with/without
valve surgery. It is also the ﬁrst to investigate longer term outcomes
such as post discharge mortality. The results showed that troponin re-
lease is signiﬁcantly reduced by RPIC, which is in agreement with
other meta-analyses in this ﬁeld [12–15]. Perhaps more pertinently, in-
dicators of clinical outcome such asmortality, ICU and hospital stay, ino-
tropic usage and new onset atrial ﬁbrillation were unaltered by RPIC.
This suggests that whilst RPIC does no harm it does not offer additional
cardioprotective effects above and beyond that already provided by
cardioplegia and volatile anaesthetics.
Our results showed that RIPC reduced troponin release as indicated
by the area under the curve. Earlier studies that only concentrated on
biomarker release also showed that RIPC reduced biomarker release
[11,13–15]. Like the current study, when data from several studies was
pooled in these earlier works, high heterogeneity was present [11,15].
In spite of this we considered this to be justiﬁed as repeated troponinsFig. 6. Troponins (area under the cumay be a more accurate method than evaluating biomarkers at a single
time point. Our work is also consistent with that of Deng et al. [16].
Our results also show that the incidence of postoperative atrial ﬁbril-
lationwas not reducedwith RIPC. Femi et al. [36] investigated the risk of
1 year mortality, myocardial infarction (MI) and stroke in patients re-
ceiving CABG at The Cleveland Clinic. They found that there was a 3.7%
increased risk of death (Hazard Ratio [HR] 1.89, 95% CI 1.42–2.53,
p b 0.001) following postoperative atrial ﬁbrillation [36]. Risk of MI
and stroke were unaffected. One of the studies investigated here deter-
mined death at one year [32]. In that study RIPC reduced the incidence
of one year mortality from 6.9% in control to 1.9% (HR 0.27, 95% CI
0.08–0.98, p = 0.046) [30].
Our work expands on that of Deng et al. [16]. We have also investi-
gated the important clinical outcome of inotrope use, although there
was no signiﬁcant difference between the control and RIPC groups.
Where our work is consistent with Deng et al. [16], is the ﬁndings that
neither ICU nor hospital stay were shortened by RIPC.
Acute kidney injury is a known complication of revascularisation,
with a recent study reporting a 2–3 times higher odds ratio for CABG
compared to percutaneous coronary intervention [35]. We however
found no differences in the serum creatinine between the control and
RIPC groups. Unfortunately parameters such as urine volume and glo-
merular ﬁltration rate were notmeasured in the studies. This prevented
us from calculating the important parameter of creatinine clearance.
Notwithstanding this, our work does support the meta-analysis by
Deng et al. [16] who also found the incidence of acute kidney injury to
be no different between control and RIPC groups.
4.1. Study limitations
RIPC did not affect post discharge mortality. However one limitation
of the current study was the different reporting periods used. In one
study where mortality was measured at 30 days, there was no differ-
ence [31]. However as the reporting time increased so did themortality
of the patients in the control group. Thuswhenmortality wasmeasured
at 6 weeks, ﬁve control patients had died compared to none in the RIPC
group [7]. Then when mortality was measured at one year 3 patients in
the RIPC group had died compared to 11 patients in the control group
[32]. This suggests that more studies using a uniform reporting period
are required.
5. Conclusions
Remote ischaemic preconditioning prior to CABG with/without
valve surgery causes no harm but does not improve clinical outcomes.rve, μg·L−1) 72 hpost-surgery.
Fig. 7. Peak post-surgery creatinine.
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CABG: coronary artery bypass grafting
CI: conﬁdence interval
HR: hazard ratio
ICU: intensive care unit
MD:mean difference
MI:myocardial infraction
MRI:magnetic resonance imaging
OR: odds ratio
RCT: randomised controlled trial
RIPC: remote ischaemic pre-conditioning
